BioCina Teams Up With CelluTx For Next-Gen CDMO Solutions

BioCina Pty Ltd., a leading global company that specializes in biologics contract development and its manufacturing, has secured exclusive rights to integrate CelluTx's advanced recombination-based plasmid system (RBPS) technology into services offered to the clients of CDMO. RBPS represents a state-of-the-art method for producing minicircle DNA (mcDNA), involving precise recombination within a bacterial host. This process separates the minicircle, which carries the desired gene, from the remainder of the plasmid backbone. This includes elements such as antibiotic resistance genes and origins of replication.

This new technology has several advantages over older mcDNA technologies, including process scalability, exceptionally high recombination efficiency, higher yields, simpler purification processes due to the clear separation of minicircles from miniplasmids, and the ability to produce larger minicircles that can accommodate complex gene cassettes. The streamlined structure of the mcDNA leads to enhanced and prolonged transgene expression and makes it less immunogenic and safer for in vivo use.

All these advantages position RBPS as a promising technique to enhance the production of mcDNA and broaden its possible uses in cell and gene therapies and other advanced medical treatments. One recent application of this technology is BioCina's cGMP program for GenomeFrontier, where RBPS plays a crucial role in scaling up Genome Frontiers CAR-T product.

Mark Womack, CEO of BioCina said that "We are pleased to announce our partnership with CelluTx enabling BioCina to exclusively provide this innovative technology to our clients around the world. We have already witnessed great success in utilizing it within our client portfolio and eagerly anticipate advancing many other client programs with the technology."

Womack Further added, "Additionally, Australia offers one of the most attractive tax incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing their products.”

CEO of CelluTx's, Maurits Geerlings, said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina."